Safety Profile and Reported Side Effects The most common side effects in Phase 2 were dose-dependent gastrointestinal symptoms including nausea, vomiting, and diarrhoea
By minimizing -arrestin involvement, CT-388 might maintain potent pharmacological activity for an extended duration, which is favorable for a chronic condition such as T2D, where long-term treatment is required
Glamoclija, L
doi: 10.1210/en.2017-00461 88 LigumskyHWolfIIsraeliSHaimsohnMFerberSKarasikAet al
Interestingly, in agreement with our results obtained in mice, a positive correlation between the plasma GLP-1 levels and the serum free T3 levels were observed in these human human study participants (Fig
Lebrun LJ, Lenaerts K, Kiers D, Pais de Barros JP, Le Guern N, Plesnik J, et al